Elanco Animal Health Incorporated (ELAN) is a global leader in the animal health industry, dedicated to innovating and delivering products and services to prevent and treat diseases in both farm animals and pets. The company offers a diverse portfolio of approximately 200 brands, marketed globally to enhance the health and wellbeing of animals. Elanco's operations focus on providing solutions for pet health and farm animal health, with a strong emphasis on sustainability and food safety .
-
Pet Health - Offers parasiticides, vaccines, and therapeutics for pets, including products like the Advantage Family, Seresto, and Credelio Family, aimed at protecting pets from parasites and treating various health conditions .
- Advantage Family - Provides flea and tick prevention solutions for pets.
- Seresto - Delivers long-lasting flea and tick protection through a collar format.
- Credelio Family - Offers oral treatments for flea and tick infestations.
-
Farm Animal - Focuses on products for cattle, swine, poultry, and aquaculture, enhancing efficiency, disease prevention, and sustainability with key products like Rumensin and Baytril .
- Rumensin - Improves feed efficiency and growth in cattle.
- Baytril - Provides antimicrobial solutions for various farm animals.
-
Contract Manufacturing - Manufactures products on behalf of third parties, supporting the production needs of other companies within the animal health industry .
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Jeffrey N. Simmons ExecutiveBoard | President and Chief Executive Officer | None | CEO of Elanco since its IPO, leading the company’s strategy and operations. No external roles mentioned. | View Report → |
James M. Meer Executive | Senior Vice President, Chief Accounting Officer | None | Joined Elanco in 2018, previously CFO at Healthx, Inc., and held senior roles at Appirio and Salesforce. | |
Shiv O’Neill Executive | Executive Vice President, General Counsel and Corporate Secretary | None | Oversees legal, compliance, and ESG matters. Previously held legal roles at Cummins Inc. and Baker & Daniels LLP. | |
Todd S. Young Executive | Executive Vice President and CFO | None | CFO since 2018, overseeing financial operations, IT, and transformation initiatives. Previously CFO at ACADIA Pharmaceuticals. | |
Art Garcia Board | Independent Director | Director at Raymond James, AEP, and ABM Industries | Former CFO of Ryder System, with expertise in finance and business integration. | |
Craig Wallace Board | Independent Director | President of C.S. Wallace Investments; Board Member at 1C and KeraVet Bio | Nearly 35 years in animal health, including leadership roles at Ceva Santé Animale and Trupanion. | |
Deborah Kochevar Board | Independent Director | Board Member at Charles River Laboratories; Senior Fellow at Tufts University | Chair of Elanco’s Innovation, Science, and Technology Committee. Extensive academic and veterinary medicine background. | |
Denise Scots-Knight Board | Independent Director | CEO and Director at Mereo BioPharma Group | Co-founder of Mereo BioPharma, with extensive experience in biopharma and oncology. | |
Kathy Turner Board | Independent Director | Board Member at Veterinarians Without Borders | Former Chief Marketing Officer at IDEXX Laboratories. Extensive experience in animal health and diagnostics. | |
Kirk McDonald Board | Independent Director | Board Member at Ziff Davis | Former CEO of GroupM North America. Expertise in marketing, digital, and technology. | |
Lawrence Kurzius Board | Chairman of the Board | Executive Chairman at McCormick & Co.; Board Member at The Cooper Companies | Chairman of Elanco since 2024, with extensive experience in consumer goods and governance. Former CEO of McCormick. | |
R. David Hoover Board | Independent Director | None | Former Chairman of Elanco (2018–2024). Previously CEO of Ball Corporation. | |
Stacey Ma Board | Independent Director | EVP at Gilead Sciences; Associate Director at CASSS | Recognized leader in biopharma development and manufacturing. Named a Top 20 Women Leader in Biopharma R&D. | |
William Doyle Board | Independent Director | Executive Chairman at Novocure; Director at ProKidney Corp. | Expertise in finance, strategy, and innovation. Former Director at Zoetis. |
-
Despite your expanded portfolio with products like Zenrelia and Credelio Quattro, competitive pressures in U.S. pet health vet clinics remain a significant headwind. Can you specify which areas you're still at a competitive disadvantage and how you plan to address these challenges?
-
With Zenrelia's launch, have you identified a percentage of veterinary practices that consider the product label a "nonstarter"? How are you mitigating concerns among these practices to drive adoption in line with your expectations?
-
Experior is expected to surpass $100 million in global sales this year. Can you quantify its current market penetration and elaborate on its long-term growth potential, especially with the recent Heifer clearances?
-
As you introduce Credelio Quattro, how do you anticipate managing potential cannibalization of your existing Credelio user base versus capturing new market share? At what point do you expect Credelio Quattro to become accretive?
-
Given your projection of mid-single-digit revenue growth but only low single-digit adjusted EBITDA growth in 2025, can you elaborate on the factors hindering operating leverage next year and your strategy for driving margin expansion in 2026 and beyond?
Research analysts who have asked questions during Elanco Animal Health earnings calls.
Jonathan Block
Stifel Financial Corp.
4 questions for ELAN
Michael Ryskin
Bank of America Merrill Lynch
4 questions for ELAN
Andrea Zayco Narvaez Alfonso
UBS
3 questions for ELAN
Erin Wilson Wright
Morgan Stanley
3 questions for ELAN
Michael DiFiore
Evercore ISI
3 questions for ELAN
Balaji Prasad
Barclays
2 questions for ELAN
Brandon Vazquez
William Blair & Company, L.L.C.
2 questions for ELAN
Christopher Schott
JPMorgan Chase & Co.
2 questions for ELAN
Daniel Clark
Leerink Partners
2 questions for ELAN
David Westenberg
Piper Sandler
2 questions for ELAN
Navann Ty Dietschi
BNP Paribas
2 questions for ELAN
Ekaterina Knyazkova
Cantor Fitzgerald
1 question for ELAN
Erin Wright
Morgan Stanley
1 question for ELAN
Mike Curry
Evercore ISI
1 question for ELAN
Navann Ty
BNP Paribas S.A.
1 question for ELAN
Ross Sparenblek
William Blair & Company
1 question for ELAN
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
TriRx Speke Ltd. | 2024 | Elanco acquired the TriRx Speke facility for $25 million in cash on November 15, 2024, to secure a critical manufacturing site that contributes approximately $160–$180 million in annual farm animal revenue; the deal included interim funding during administration and long-term supply chain continuity provisions. |
NutriQuest LLC | 2023 | Elanco’s acquisition of NutriQuest LLC involved a total purchase consideration of $58 million, including $16 million in upfront cash, $5 million deferred, and a contingent payment structure of up to $85 million, aimed at bolstering its product pipeline and innovation revenue through key marketed and intangible assets. |
NutriQuest Brazil | 2023 | The acquisition of NutriQuest Brazil closed on August 1, 2023, for a total of $19 million (with $3 million cash at closing and $16 million payable through 2026, subject to conditions), securing inventory and distribution rights alongside preliminary purchase price allocations and amortization of intangible assets over nine years. |
KindredBio | 2021 | Elanco completed the KindredBio acquisition for approximately $444 million (at $9.25 per share) on August 27, 2021, strategically enhancing its pet health portfolio—especially in dermatology—with a promising pipeline of biologics and monoclonal antibodies, including a canine parvovirus treatment expected to drive long-term revenue growth. |
Recent press releases and 8-K filings for ELAN.
- Elanco Animal Health has received the first-ever Emergency Use Authorization (EUA) from the U.S. FDA for its Credelio tablets to treat New World screwworm infestations in dogs.
- This authorization addresses a re-emerging threat, as the screwworm parasite, previously eradicated from the U.S., has been detected near the southern border.
- Credelio, an existing flea and tick control drug, demonstrated 100% efficacy in clearing screwworm larvae within 24 hours in a small study, though the authorization is temporary and potential side effects include tremors and seizures.
- Elanco Animal Health has secured the first-ever FDA Emergency Use Authorization (EUA) for its product Credelio™ (lotilaner) to treat New World screwworm (NWS) infestations in dogs.
- This authorization provides a critical, ready-now treatment option for veterinarians and pet owners, as NWS cases have been confirmed less than 70 miles south of the U.S.-Mexico border.
- The EUA is supported by a study demonstrating 100% efficacy of Credelio against NWS larvae within 24 hours in naturally infested dogs.
- While Credelio is not specifically approved for NWS treatment, it is approved for other uses like flea and tick control, which is important for preventing NWS infestations.
- Elanco Animal Health announced that the FDA has approved updates to the U.S. Zenrelia label, removing language regarding the risk of fatal vaccine-induced disease from modified live virus vaccines. This decision follows the FDA's evaluation of supplemental scientific data.
- The updated label aligns the U.S. Zenrelia label more closely with those in markets such as the European Union, Great Britain, Brazil, and Japan.
- Zenrelia, an oral JAK inhibitor for canine skin allergies approved in September 2024, has treated over half a million dogs globally and is experiencing strong market adoption, with 80% of U.S. clinics re-ordering the product.
- The label's Boxed Warning continues to advise discontinuing Zenrelia for 28 days to 3 months prior to vaccination and withholding it for 28 days after vaccination due to the risk of an inadequate immune response to vaccines.
- Elanco's accelerated growth is attributed to innovation in both the pet and livestock markets, driven by the humanization of pets and animal protein trends.
- Key innovations include Credelio Quattro, a parasiticide product that captured 14% market share in four months in a $6 billion market, and dermatology products for pets in a $2 billion market.
- Over 50% of the industry is on the livestock side, where Elanco is bringing innovation to improve productivity in beef and dairy.
- Tariffs and trade policies are projected to impact Elanco's business by $10 million to $14 million this year, which is considered manageable and within guidance.
- Elanco Animal Health Inc. announced that its product, Zenrelia™ (ilunocitinib), has received European Commission approval.
- Zenrelia is a once-daily oral JAK inhibitor for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs.
- The company plans to begin the product launch immediately, with supply expected in Q3 2025.
- A head-to-head study demonstrated that Zenrelia is at least as effective as the market incumbent, Apoquel.
- Elanco Animal Health Inc. announced the USDA approval of TruCan Ultra CIV H3N2/H3N8, a new canine influenza vaccine designed to provide broad respiratory disease protection.
- This vaccine is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering protection against H3N2 and H3N8, and it uniquely demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.
- TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines and is now available for pre-order, with shipping anticipated within the next 30 business days.
- Elanco Animal Health Inc. released its 2024 Impact Report on June 26, 2025, introducing a new framework centered on four key communities of impact: animals, customers, society, and people.
- The company's key innovations, including Zenrelia, Credelio Quattro, and Pradalex, generated $461 million in revenue in 2024, surpassing its innovation revenue contribution target of $420 million to $450 million.
- Elanco launched Bovaer®, a methane-reducing feed ingredient, and enrolled 11% of the U.S. dairy herd into its UpLook database, enabling U.S. dairy farmers to earn approximately $10 million in net returns from carbon credit monetization.
- The company achieved a 71% Employee Engagement Score as of Q1 2025, a 4% increase from the same period a year ago, and recorded a 37% decrease in Days Away, Restricted, or Transferred (DART).
- Elanco Animal Health announced Zenrelia (ilunocitinib) received a positive opinion from the European Medicines Agency’s CVMP, endorsing its efficacy and safety for treating pruritus and atopic dermatitis in dogs.
- The opinion initiates the marketing authorization process in the EU, expected to conclude within 60 days.
- Elanco plans to launch Zenrelia in EU markets with supply available before the end of Q3 2025.
- Zenrelia is the company’s fastest globalized product, achieving eight major regulatory approvals in 18 months and already available in Brazil, Canada, Japan, and the US, with approvals in Australia and the UK anticipated in 2025.
- CFO transition: The company announced a proactive CFO change, appointing Bob VanHimbergen from Hillenbrand—with 30 years of experience—to lead the next era, while current CFO Todd remains through August for a smooth handover.
- Strong Q1 performance: The call highlighted a robust quarter with accelerating growth and raised guidance to 4-6%, including notable innovation revenue of $198 million, underscoring the value of innovation in the company's portfolio.
- Product innovation momentum: Early success was reported for key products such as Credelio Quattro, which quickly captured a 10% market share and is supported by differentiated features enhancing its market impact.
- Margin expansion and balance sheet improvement: The firm is advancing multiple initiatives to drive margin expansion and reduce leverage, focusing on mix improvements, pricing strategies, and cost management to strengthen its balance sheet.
- Robert (Bob) VanHimbergen has been named Executive Vice President and Chief Financial Officer, effective July 7, 2025, succeeding Todd Young who will serve as an advisor through August 31, 2025.
- VanHimbergen brings nearly three decades of financial leadership experience, having held senior roles at Hillenbrand, Inc. and Johnson Controls.
- The company also reaffirmed its Q2 and full year guidance, reflecting confidence in sustained growth and strategic execution.